Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631229 | 1.00 | CXCR3 (0.38) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL549517 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL2699742 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL2699738 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL2699981 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL549916 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL550534 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL549983 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL549917 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 | |
| SCHEMBL549516 | 0.89 | HSD11B1 (0.36) | CXCR3HSD11B1HCRTR2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | claimed |
| EP-1957494-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007067504-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-06-14 | — | — | WO | claimed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | claimed |
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| EP-1957494-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007067504-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | CXCR3 2494/4885HSD11B1 1/4885HCRTR2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.